CHAPEL HILL, NC - The WIN (Worldwide Innovative Networking in Personalized Cancer Medicine) Consortium is taking place today through Friday in Paris’ Palais des Congrès. The symposium brings together a broad international audience of oncology experts to discuss the challenges of early cancer diagnosis; optimum ways to select and deliver personalized treatment; and how to translate these concepts into the clinic.
N.C. Cancer Hospital Physician-in-chief Richard Goldberg, MD, is one of an elite group of presenters asked to participate in this year’s symposium. He presented today, July 7, on “Optimal Ways to Integrate Chemotherapy and Targeted Therapies in Colorectal Cancer.” Among his fellow presenters are John Medelsohn, MD, of MD Anderson Cancer Center who is also a member of the University Cancer Research Fund advisory board; Leroy Hood, MD, PhD, of the Institute for Systems Biology; Olli Kallioniemi, MD, PhD, of the Institute for Molecular Medicine at the University of Helsinki, Finland; Richard Schilsky, MD, of the University of Chicago Medical Center; and Jean Charles Soria, MD, of the Institut Gustave Roussy in France.
The WIN Consortium is a joint initiative of the Institut Gustave Roussy and the University of Texas M. D. Anderson Cancer Center, in association with other leading cancer care institutions around the World. The Consortium aims to build new strategic alliances in oncology, creating innovative drug development programs and accelerating clinical trials and validation of new drugs for personalized cancer care.
The WIN Symposium , supported by media partner the Nature Publishing Group, is an annual gathering of oncology experts worldwide to discuss breakthrough scientific technologies and achievements in personalized cancer medicine, with a special focus on individualized treatment and early diagnosis of cancer.